Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11306685 | 0.86 | LMNA (0.63) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL6542484 | 0.85 | LMNA (0.61) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL30100412 | 0.85 | MRGPRX4 (0.64) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL48961 | 0.85 | MRGPRX4 (0.64) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL257135 | 0.85 | LMNA (0.61) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL29924548 | 0.85 | FLT1 (0.55) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL498726 | 0.85 | FLT1 (0.55) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL16951330 | 0.84 | LMNA (0.56) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL1095516 | 0.83 | MEN1 (0.64) | ALDH1A1LMNAKCNMA1KMT2AMEN1 | |
| SCHEMBL726267 | 0.83 | MAPT (0.60) | ALDH1A1LMNAKCNMA1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008063781-A2 | CHEMICAL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | claimed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024064827-A2 | SUBSTITUTED 2-CINNAMOYLPHENYL BENZOATES AND RELATED HETEROCYCLES AS WNT INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| CN-109970743-B | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10995061-B2 | SPAK kinase inhibitors as neuroprotective agents | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-0203791-B1 | SPIRO-IMIDAZOLIDINES AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| EP-0203791-A1 | Spiro-imidazolidines as aldose reductase inhibitors | PFIZER INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| US-4575507-A | COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1986-03-11 | — | — | US | disclosed |
| US-4251546-A | Process for killing internal helminths using certain 1,1-bis-(2-substituted-3-nitrophenyl)alkane or alkylene derivatives | ICI AUSTRALIA LIMITED (AU) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | ALDH1A1 1375/4885LMNA 4756/4885KCNMA1 3701/4885 |
| US-10995061-B2 | SPAK kinase inhibitors as neuroprotective agents | SBK1, DAPK2, SPAST | ALDH1A1 3598/4885LMNA 1790/4885KCNMA1 1767/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | ALDH1A1 1375/4885LMNA 4756/4885KCNMA1 3701/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ALDH1A1 1488/4885LMNA 4313/4885KCNMA1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.